The ecosystem of the human gut consists of trillions of bacteria forming a bioreactor that is
fueled by dietary macronutrients to produce bioactive compounds. These microbiota-derived …

NAFLD is now the most common cause of liver disease in Western countries. This Review
explores the links between NAFLD, the metabolic syndrome, dysbiosis, poor diet and gut …

Background Primary biliary cholangitis (formerly called primary biliary cirrhosis) can
progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin …

Summary Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis,
concentrations of liver enzymes, and insulin resistance in murine models of fatty liver …

Background: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes
or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone …

The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis,
treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the …

Background & Aims Elafibranor is an agonist of the peroxisome proliferator− activated
receptor-α and peroxisome proliferator− activated receptor-δ. Elafibranor improves insulin …

Non-alcoholic fatty liver (NAFLD) is the most common liver disease worldwide, progressing
from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic …

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver
diseases in the Western society and its prevalence is likely to rise even further. An …